251 related articles for article (PubMed ID: 16178800)
1. Decreasing the metastatic potential in cancers--targeting the heparan sulfate proteoglycans.
Fjeldstad K; Kolset SO
Curr Drug Targets; 2005 Sep; 6(6):665-82. PubMed ID: 16178800
[TBL] [Abstract][Full Text] [Related]
2. Heparanase degrades syndecan-1 and perlecan heparan sulfate: functional implications for tumor cell invasion.
Reiland J; Sanderson RD; Waguespack M; Barker SA; Long R; Carson DD; Marchetti D
J Biol Chem; 2004 Feb; 279(9):8047-55. PubMed ID: 14630925
[TBL] [Abstract][Full Text] [Related]
3. Heparan sulfate proteoglycans and cancer.
Blackhall FH; Merry CL; Davies EJ; Jayson GC
Br J Cancer; 2001 Oct; 85(8):1094-8. PubMed ID: 11710818
[TBL] [Abstract][Full Text] [Related]
4. Specific structural features of syndecans and heparan sulfate chains are needed for cell signaling.
Lopes CC; Dietrich CP; Nader HB
Braz J Med Biol Res; 2006 Feb; 39(2):157-67. PubMed ID: 16470302
[TBL] [Abstract][Full Text] [Related]
5. Heparan sulfate proteoglycans as adhesive and anti-invasive molecules. Syndecans and glypican have distinct functions.
Liu W; Litwack ED; Stanley MJ; Langford JK; Lander AD; Sanderson RD
J Biol Chem; 1998 Aug; 273(35):22825-32. PubMed ID: 9712917
[TBL] [Abstract][Full Text] [Related]
6. The Glycosaminoglycan Side Chains and Modular Core Proteins of Heparan Sulphate Proteoglycans and the Varied Ways They Provide Tissue Protection by Regulating Physiological Processes and Cellular Behaviour.
Farrugia BL; Melrose J
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762403
[TBL] [Abstract][Full Text] [Related]
7. Heparan sulfate proteoglycans on the cell surface: versatile coordinators of cellular functions.
Tumova S; Woods A; Couchman JR
Int J Biochem Cell Biol; 2000 Mar; 32(3):269-88. PubMed ID: 10716625
[TBL] [Abstract][Full Text] [Related]
8. [Human heparanase: roles in invasion and metastasis of cancer].
Gohji K; Katsuoka Y; Okamoto M; Kamidono S; Kitazawa S; Toyoshima M; Dong J; Nakajima M
Hinyokika Kiyo; 2000 Oct; 46(10):757-62. PubMed ID: 11215206
[TBL] [Abstract][Full Text] [Related]
9. Oligomannurarate sulfate, a novel heparanase inhibitor simultaneously targeting basic fibroblast growth factor, combats tumor angiogenesis and metastasis.
Zhao H; Liu H; Chen Y; Xin X; Li J; Hou Y; Zhang Z; Zhang X; Xie C; Geng M; Ding J
Cancer Res; 2006 Sep; 66(17):8779-87. PubMed ID: 16951194
[TBL] [Abstract][Full Text] [Related]
10. Anionic biopolyelectrolytes of the syndecan/perlecan superfamily: physicochemical properties and medical significance.
Siegel G; Malmsten M; Ermilov E
Adv Colloid Interface Sci; 2014 Mar; 205():275-318. PubMed ID: 24534475
[TBL] [Abstract][Full Text] [Related]
11. Proteoglycans in health and disease: novel roles for proteoglycans in malignancy and their pharmacological targeting.
Theocharis AD; Skandalis SS; Tzanakakis GN; Karamanos NK
FEBS J; 2010 Oct; 277(19):3904-23. PubMed ID: 20840587
[TBL] [Abstract][Full Text] [Related]
12. Specific genes involved in synthesis and editing of heparan sulfate proteoglycans show altered expression patterns in breast cancer.
Fernández-Vega I; García O; Crespo A; Castañón S; Menéndez P; Astudillo A; Quirós LM
BMC Cancer; 2013 Jan; 13():24. PubMed ID: 23327652
[TBL] [Abstract][Full Text] [Related]
13. A functional heparan sulfate mimetic implicates both heparanase and heparan sulfate in tumor angiogenesis and invasion in a mouse model of multistage cancer.
Joyce JA; Freeman C; Meyer-Morse N; Parish CR; Hanahan D
Oncogene; 2005 Jun; 24(25):4037-51. PubMed ID: 15806157
[TBL] [Abstract][Full Text] [Related]
14. Development of heparanase inhibitors for anti-cancer therapy.
Miao HQ; Liu H; Navarro E; Kussie P; Zhu Z
Curr Med Chem; 2006; 13(18):2101-11. PubMed ID: 16918340
[TBL] [Abstract][Full Text] [Related]
15. Heparan Sulfate Proteoglycans Can Promote Opposite Effects on Adhesion and Directional Migration of Different Cancer Cells.
Depau L; Brunetti J; Falciani C; Mandarini E; Riolo G; Zanchi M; Karousou E; Passi A; Pini A; Bracci L
J Med Chem; 2020 Dec; 63(24):15997-16011. PubMed ID: 33284606
[TBL] [Abstract][Full Text] [Related]
16. Endorepellin, a novel inhibitor of angiogenesis derived from the C terminus of perlecan.
Mongiat M; Sweeney SM; San Antonio JD; Fu J; Iozzo RV
J Biol Chem; 2003 Feb; 278(6):4238-49. PubMed ID: 12435733
[TBL] [Abstract][Full Text] [Related]
17. Heparan sulfate proteoglycans and heparanase--partners in osteolytic tumor growth and metastasis.
Sanderson RD; Yang Y; Suva LJ; Kelly T
Matrix Biol; 2004 Oct; 23(6):341-52. PubMed ID: 15533755
[TBL] [Abstract][Full Text] [Related]
18. Matrix glycosaminoglycans in the growth phase of fibroblasts: more of the story in wound healing.
Kosir MA; Quinn CC; Wang W; Tromp G
J Surg Res; 2000 Jul; 92(1):45-52. PubMed ID: 10864481
[TBL] [Abstract][Full Text] [Related]
19. The heparanase/heparan sulfate proteoglycan axis: A potential new therapeutic target in sarcomas.
Cassinelli G; Zaffaroni N; Lanzi C
Cancer Lett; 2016 Nov; 382(2):245-254. PubMed ID: 27666777
[TBL] [Abstract][Full Text] [Related]
20. Cell surface heparan sulfate proteoglycans control the response of renal interstitial fibroblasts to fibroblast growth factor-2.
Clayton A; Thomas J; Thomas GJ; Davies M; Steadman R
Kidney Int; 2001 Jun; 59(6):2084-94. PubMed ID: 11380810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
